Clinical Trial Search

Primary: Percentage of Patients Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours of the First Dose — 34.2; 9.9 percentage of participants — p=<0.001

Primary: Number of Participants Who Achieved Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 — 241; 230 Participants

Primary: The Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly…

Primary: Baseline Average Number of Daily Incontinence Episodes — 5.4; 5.4 Number of episodes

Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — -13.99; -5.23; 43.83; 45.81 points on a scale — p=<0.0001

Primary: Average Change From Baseline in American Orthopedic Foot and Ankle Society(AOFAS) at 12 Months Post-surgery — 16.93 scores

Primary: Peak Concentration (Cmax) — 567; 1527 ng/mL

Primary: Number of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497)…

Primary: Median Percentage of Nights Without Heartburn Over 4 Weeks as Assessed by Daily Diary. — 35.7; 73.1 Percentage of nights — p=<0.001

Primary: Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS) at 8 Weeks. — -12.8; -13.4; -10.1 Units on a scale

Primary: Percentage of Subjects With Seroprotection, in Healthy Adults 18 to 64 Years of Age — 93; 96; 91; 99 Percentages of participants

Primary: Disease Activity Score Using 28-joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4ESR) by Treatment Period. — 3.26; 3.13 units on scale

Primary: Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18 — 6; 0 participants

Primary: Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose — 2.2; 2.0; 1.4; 1.6 units on a scale — p=0.010

Primary: Frequency of All HAE Attacks — 3.00; 0.21 attacks per month